Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding Phase 2 study of burosumab (anti-FGF23 antibody KRN23) in pediatric X-linked hypophosphatemia
2014-000406-35Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of burosumab in X-linked hypophosphataemia (XLH) and Hereditary Hypophosphatemic Rickets (XLH) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Pharmacodynamic effects. Started Mar 2014; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)Hereditary Hypophosphatemic Rickets (XLH)
Beyond the preview
Go deeper on 2014-000406-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000406-35.